References
- Momenimovahed Z, Tiznobaik A, Taheri S, et al. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287–289.
- Tew WP, Lacchetti C, Ellis A, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(30):3468–3493.
- Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):245–259.
- Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366–374.
- Bonadio R, Fogace R, Miranda V, et al. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics (Sao Paulo). 2018;73(suppl. 1):e450s.
- Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403–2415.
- González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402.
- Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as First-Line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–2428.
- Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017;390(10106):1949–1961.
- Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in Platinum-Sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164.
- Kim DS, Camacho CV, Kraus WL. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med. 2021;53(1):42–51.
- Kim DS, Camacho CV, Nagari A, et al. Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the RNA helicase DDX21. Mol Cell. 2019;75(6):1270–1285.
- Huang D, Kim DS, Kraus WL. Specific binding of snoRNAs to PARP-1 promotes NAD+-dependent catalytic activation. Biochemistry. 2020;59(16):1559–1564.
- Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374(9698):1371–1382.
- Wu XH, Zhu JQ, Yin RT, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2021;32(4):512–521.
- Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–2612.
- Current Approvals. [cited 2021 Jul 2]. Available from: https://oncologypro.esmo.org/oncology-in-practice/anti-cancer-agents-and-biological-therapy/parp-inhibition-and-dna-damage-response-ddr/parp-inhibitors/clinical-activity/ovarian-cancer/current-approvals. 2019.
- Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505.
- Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284.
- Poveda A, Floquet A, Ledermann JA, et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol. 2020;38(suppl. 15):6002–6002.
- Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in Platinum-Sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–1392.
- Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579–1589.
- Hettle R, McCrea C, Lee CK, et al. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer. Ther Adv Med Oncol. 2021;13:17588359211049639.
- ZEJULA (niraparib) U.S. Approval. [cited 2021 Jul 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. 2020.
- LYNPARZA (olaparib) U.S. Approval. [cited 2021 Jul 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. 2018.
- RUBRACA (rucaparib) U.S. Approval. [cited 2021 Jul 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf. 2018.
- Lynparza-epar-product-information. [cited 2021 Jul 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. 2018.
- Rubraca-epar-product-information. [cited 2021 Jul 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/rubraca-epar-product-information_en.pdf. 2018.
- Zejula-epar-product-information. [cited 2021 Jul 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/zejula-epar-product-information_en.pdf. 2020.
- Gonzalez R, Havrilesky LJ, Myers ER, et al. Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gynecol Oncol. 2020;159(2):483–490.
- Penn CA, Wong MS, Walsh CS. Cost-effectiveness of maintenance therapy based on molecular classification following treatment of primary epithelial ovarian cancer in the United States. JAMA Netw Open. 2020;3(12):e2028620.
- Della Corte L, Foreste V, Di Filippo C, et al. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know. Expert Opin Investig Drugs. 2021;30(5):543–554.
- Al Hadidi S, Aburahma A, Badami S, et al. PARP (poly(ADP-Ribose) polymerase) inhibitors in platinum-sensitive recurrent ovarian cancer: a meta-analysis of randomized controlled trials. Oncol Res Treat. 2018;41(4):226–235.
- Staropoli N, Ciliberto D, Del Giudice T, et al. The era of PARP inhibitors in ovarian cancer: "class action" or not? A systematic review and Meta-analysis. Crit Rev Oncol Hematol. 2018;131:83–89.
- Tomao F, Bardhi E, Di Pinto A, et al. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials according to BRCA mutational status. Cancer Treat Rev. 2019;80:101909.
- Wang Y, Ren F, Song Z, et al. PARP inhibitors in patients with newly diagnosed advanced ovarian cancer: a meta-analysis of randomized clinical trials. Front Oncol. 2020;10(1204).
- Cheng H, Yang J, Liu H, et al. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and Meta-analysis. Arch Gynecol Obstet. 2021;304(2):285–296.